RECRUITINGINTERVENTIONAL
Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI
About This Trial
This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.
Who May Be Eligible (Plain English)
Who May Qualify:
- Fabry disease;
- Age ≥ 18 years.
Who Should NOT Join This Trial:
- History of myocardial infarction;
- Contraindication to MRI.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Fabry disease;
* Age ≥ 18 years.
Exclusion Criteria:
* History of myocardial infarction;
* Contraindication to MRI.
Treatments Being Tested
DIAGNOSTIC_TEST
Cardiac MRI, ECG/Holter and Blood Biomarkers
Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
Locations (1)
University Health Network
Toronto, Ontario, Canada